Trial Details

Not Recruiting
Basic Information
Clinical ID c5014
Identifier ISRCTN15354495
Trial Title A Phase III, multicentre, randomised trial comparing SARS-CoV-2 re-boost vaccine strategies in immunocompromised patients
Trial URL Visit Original Page
Study Information
Study Results

Yes

Conditions Patients with 1) solid cancer; 2) lymphoid malignancies; 3) immune-mediated rheumatic diseases; 4) end stage kidney disease; 5) liver disease; 6) inflammatory bowel disease on immune suppressive therapy; 7) haematopoietic stem cell transplant; and 8) prim
Interventions For the main study randomised comparison, patients will randomised using a minimisation program (developed by the CRCTU) in a 1:1 ratio. Patients will be randomised to receive: Arm 1: Pfizer SARS-CoV2 VaccineArm 2: Moderna SARS-CoV2 Vaccine<b
Participant Information
Sponsor University of Birmingham
City NULL
Country/Region United Kingdom
Enrollment Criteria
Sex Requirement ALL
Age Requirement NULL
Study Design
Study Type Interventional
Phase PHASE3
Time Information
Start Date NULL
Primary Completion Date NULL
Completion Date NULL